Bernstein Harold 4

What Happened
Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics (MAZE), exercised stock options to acquire 14,609 shares at a $10.42 strike ($152,226) on July 1, 2026, and promptly sold those 14,609 shares in the open market for aggregate proceeds of about $436,864 (sales reported as $400,460 and $36,404). A separate reporting line shows the derivative/option position disposed at $0.00, reflecting the settlement/retirement of the exercised options. Net proceeds before fees and taxes were approximately $284,638.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 2, 2026.
• Exercise/acquisition: 14,609 shares at $10.42 each = $152,226.
• Open-market sales: 13,409 shares at a weighted avg $29.86 = $400,460 (sales ranged $29.24–$30.23); 1,200 shares at a weighted avg $30.34 = $36,404 (sales ranged $30.24–$30.42).
• Report shows the derivative/option position disposed at $0.00 (technical entry for settlement of exercised options).
• Footnote: sales were made under a Rule 10b5-1 trading plan adopted Sept 29, 2025.
• Shares owned after the transactions are not specified in the provided excerpt.

Context

• This was an exercise of vested options followed by immediate sales (commonly called a cashless exercise/net sale plus settlement) rather than a fresh open‑market purchase—so it results in net selling into the market rather than an additional insider stake.
• The option vesting schedule noted: 1/4 vested Oct 3, 2023, then monthly 1/48th thereafter, subject to continued service.
• The presence of a 10b5-1 plan indicates the sales were pre-arranged and likely routine; the filing appears timely (filed the day after the transactions).